ROTFL. It was one patient in an early stage trial, They still need to complete the rest of the Phase II, then Phases III and IV.
Only 4% (19 our of 430) of drugs evaluated for ischemic stroke between 1995-2015. ever reached the market.Acta Pharm Sin B. 2016 Nov; 6(6): 522–530.Published online 2016 Jul 28. doi: 10.1016/j.apsb.2016.06.013PMCID: PMC5071630PMID: 27818918The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995–2015
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071630/
The reason why the price doesn't move on news is because not everybody is as ignorant about the drug approval process or as wildly overconfident as CUV holders.
ROTFL. It was one patient in an early stage trial, They still...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |